- Home
- UROY vs ALDX Comparison
UROY vs ALDX Comparison
Compare UROY & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UROY
- ALDX
- Stock Information
- Founded
- UROY 2017
- ALDX 2004
- Country
- UROY Canada
- ALDX United States
- Employees
- UROY N/A
- ALDX N/A
- Industry
- UROY
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- UROY
- ALDX Health Care
- Exchange
- UROY Nasdaq
- ALDX Nasdaq
- Market Cap
- UROY 351.1M
- ALDX 319.4M
- IPO Year
- UROY N/A
- ALDX 2014
- Fundamental
- Price
- UROY $2.68
- ALDX $4.81
- Analyst Decision
- UROY Strong Buy
- ALDX Strong Buy
- Analyst Count
- UROY 2
- ALDX 2
- Target Price
- UROY $5.60
- ALDX $10.00
- AVG Volume (30 Days)
- UROY 2.2M
- ALDX 544.4K
- Earning Date
- UROY 12-11-2024
- ALDX 11-07-2024
- Dividend Yield
- UROY N/A
- ALDX N/A
- EPS Growth
- UROY N/A
- ALDX N/A
- EPS
- UROY 0.05
- ALDX N/A
- Revenue
- UROY $30,916,580.00
- ALDX N/A
- Revenue This Year
- UROY N/A
- ALDX N/A
- Revenue Next Year
- UROY $72.53
- ALDX $25.36
- P/E Ratio
- UROY $55.04
- ALDX N/A
- Revenue Growth
- UROY 208.26
- ALDX N/A
- 52 Week Low
- UROY $1.86
- ALDX $2.43
- 52 Week High
- UROY $3.76
- ALDX $6.55
- Technical
- Relative Strength Index (RSI)
- UROY 49.79
- ALDX 44.70
- Support Level
- UROY $2.62
- ALDX $4.09
- Resistance Level
- UROY $2.83
- ALDX $5.01
- Average True Range (ATR)
- UROY 0.16
- ALDX 0.40
- MACD
- UROY -0.01
- ALDX -0.03
- Stochastic Oscillator
- UROY 54.55
- ALDX 43.64
About UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is the investment in a portfolio of uranium interests.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.